DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026)

DiaMedica Therapeutics has reported Common Equity for 10 years, with the latest figure at $47.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 39.11% year-over-year to $47.2 million; the trailing twelve-month figure through Mar 2026 stood at $47.2 million (up 39.11% YoY), and the FY2025 full-year result was $56.1 million, up 37.8% from the prior year.
• Common Equity for Q1 2026 stood at $47.2 million, down from $56.1 million in the prior quarter.
• The five-year high for Common Equity was $59.7 million in Q2 2023, with the low at $27.0 million in Q1 2023.
• Historically, Common Equity has averaged $43.7 million across 5 years, with a median of $46.3 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity jumped 85.62% — and 2025, when it tumbled 49.13%.
• DiaMedica Therapeutics' Common Equity stood at $31.8 million in 2022, then jumped by 60.42% to $51.1 million in 2023, then fell by 20.25% to $40.7 million in 2024, then soared by 37.8% to $56.1 million in 2025, then fell by 15.82% to $47.2 million in 2026.
• The last three Common Equity figures came in at $47.2 million (Q1 2026), $56.1 million (Q4 2025), and $51.6 million (Q3 2025), per Business Quant data.